Search research articles
Contact Us
Filters
Showing results (1-10 of 91) with videos related to
Page
of 10
Sort By:
Molecular Oncology
|
May 15, 2010
Molecular basis for therapy resistance
Per E Lønning
Trends in Cancer
|
December 28, 2020
Assessing Novel Therapies Based on Late-Stage Efficacy: A Dangerous Concept?
Per E Lønning
Drugs & Aging
|
June 1, 2002
Aromatase inhibitors and inactivators for breast cancer therapy
Per E Lønning
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 11, 2005
Exemestane for breast cancer prevention: a feasible strategy?
Per E Lønning
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 30, 2008
Endocrine therapy and bone loss in breast cancer: time to close in the RANK(L)?
Per E Lønning
Therapeutic Advances in Medical Oncology
|
May 17, 2012
Poor-prognosis estrogen receptor- positive disease: present and future clinical solutions
Per E Lønning
Lab on a Chip
|
August 18, 2017
Comment on "Towards a personalized approach to aromatase inhibitor therapy: a digital microfluidic platform for rapid analysis of estradiol in core-needle-biopsies" by S. Abdulwahab, A. H. C. Ng, M. D. Chamberlain, H. Ahmado, L.-A. Behan, H. Gomaa, R. F. Casper and A. R. Wheeler, Lab Chip, 2017, 17, 1594
Per E Lønning
Oncotarget
|
March 26, 2011
MDM2 promoter SNP285 and SNP309; phylogeny and impact on cancer risk
Stian Knappskog, Per E Lønning
The Journal of Steroid Biochemistry and Molecular Biology
|
November 13, 2007
Aromatase inhibitors: assessment of biochemical efficacy measured by total body aromatase inhibition and tissue estrogen suppression
Per E Lønning, Jürgen Geisler
Critical Reviews in Oncology/Hematology
|
December 13, 2005
Aromatase inhibitors as adjuvant treatment of breast cancer
Jürgen Geisler, Per E Lønning
Page
of 10
Search research articles
Search
Showing results (1-10 of 91) with videos related to
Sort By:
Page
of 10
Molecular Oncology
|
May 15, 2010
Molecular basis for therapy resistance
Per E Lønning
Trends in Cancer
|
December 28, 2020
Assessing Novel Therapies Based on Late-Stage Efficacy: A Dangerous Concept?
Per E Lønning
Drugs & Aging
|
June 1, 2002
Aromatase inhibitors and inactivators for breast cancer therapy
Per E Lønning
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 11, 2005
Exemestane for breast cancer prevention: a feasible strategy?
Per E Lønning
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 30, 2008
Endocrine therapy and bone loss in breast cancer: time to close in the RANK(L)?
Per E Lønning
Therapeutic Advances in Medical Oncology
|
May 17, 2012
Poor-prognosis estrogen receptor- positive disease: present and future clinical solutions
Per E Lønning
Lab on a Chip
|
August 18, 2017
Comment on "Towards a personalized approach to aromatase inhibitor therapy: a digital microfluidic platform for rapid analysis of estradiol in core-needle-biopsies" by S. Abdulwahab, A. H. C. Ng, M. D. Chamberlain, H. Ahmado, L.-A. Behan, H. Gomaa, R. F. Casper and A. R. Wheeler, Lab Chip, 2017, 17, 1594
Per E Lønning
Oncotarget
|
March 26, 2011
MDM2 promoter SNP285 and SNP309; phylogeny and impact on cancer risk
Stian Knappskog, Per E Lønning
The Journal of Steroid Biochemistry and Molecular Biology
|
November 13, 2007
Aromatase inhibitors: assessment of biochemical efficacy measured by total body aromatase inhibition and tissue estrogen suppression
Per E Lønning, Jürgen Geisler
Critical Reviews in Oncology/Hematology
|
December 13, 2005
Aromatase inhibitors as adjuvant treatment of breast cancer
Jürgen Geisler, Per E Lønning
Page
of 10